Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Salehi A. M.) "

Sökning: WFRF:(Salehi A. M.)

  • Resultat 1-10 av 27
  • [1]23Nästa
Sortera/gruppera träfflistan
  • Aslani, H., et al. (författare)
  • Iranian Joint Registry (Iranian National Hip and Knee Arthroplasty Registry)
  • 2016
  • Ingår i: Archives of Bone and Joint Surgery-Abjs. - 2345-4644. ; 4:2, s. 192-196
  • Tidskriftsartikel (refereegranskat)abstract
    • Periodic evaluation and monitoring the health and economic outcome of joint replacement surgery is a common and popular process under the territory of joint registries in many countries. In this article we introduce the methodology used for the foundation of the National Iranian Joint Registry ( IJR) with a joint collaboration of the Social Security Organization (SSO) and academic research departments considering the requirements of the Iran's Ministry of Health and Education.
  • Hamilton, A., et al. (författare)
  • Adrenaline Stimulates Glucagon Secretion by Tpc2-Dependent Ca2+ Mobilization From Acidic Stores in Pancreatic α-Cells
  • 2018
  • Ingår i: Diabetes. - American Diabetes Association Inc.. - 1939-327X. ; 67:6, s. 1128-1139
  • Tidskriftsartikel (refereegranskat)abstract
    • Adrenaline is a powerful stimulus of glucagon secretion. It acts by activation of β-adrenergic receptors, but the downstream mechanisms have only been partially elucidated. Here, we have examined the effects of adrenaline in mouse and human α-cells by a combination of electrophysiology, imaging of Ca2+ and PKA activity, and hormone release measurements. We found that stimulation of glucagon secretion correlated with a PKA- and EPAC2-dependent (inhibited by PKI and ESI-05, respectively) elevation of [Ca2+]i in α-cells, which occurred without stimulation of electrical activity and persisted in the absence of extracellular Ca2+ but was sensitive to ryanodine, bafilomycin, and thapsigargin. Adrenaline also increased [Ca2+]i in α-cells in human islets. Genetic or pharmacological inhibition of the Tpc2 channel (that mediates Ca2+ release from acidic intracellular stores) abolished the stimulatory effect of adrenaline on glucagon secretion and reduced the elevation of [Ca2+]i Furthermore, in Tpc2-deficient islets, ryanodine exerted no additive inhibitory effect. These data suggest that β-adrenergic stimulation of glucagon secretion is controlled by a hierarchy of [Ca2+]i signaling in the α-cell that is initiated by cAMP-induced Tpc2-dependent Ca2+ release from the acidic stores and further amplified by Ca2+-induced Ca2+ release from the sarco/endoplasmic reticulum.
  • Nilsson, I. A. K., et al. (författare)
  • Plasma neurofilament light chain concentration is increased in anorexia nervosa
  • 2019
  • Ingår i: Translational Psychiatry. - 2158-3188. ; 9
  • Tidskriftsartikel (refereegranskat)abstract
    • Anorexia nervosa (AN) is a severe psychiatric disorder with high mortality and, to a large extent, unknown pathophysiology. Structural brain differences, such as global or focal reductions in grey or white matter volumes, as well as enlargement of the sulci and the ventricles, have repeatedly been observed in individuals with AN. However, many of the documented aberrances normalize with weight recovery, even though some studies show enduring changes. To further explore whether AN is associated with neuronal damage, we analysed the levels of neurofilament light chain (NfL), a marker reflecting ongoing neuronal injury, in plasma samples from females with AN, females recovered from AN (AN-REC) and normal-weight age-matched female controls (CTRLS). We detected significantly increased plasma levels of NfL in AN vs CTRLS (median(AN) = 15.6 pg/ml, IQR(AN) = 12.1-21.3, median(CTRL) = 9.3 pg/ml, IQR(CTRL) = 6.4-12.9, and p < 0.0001), AN vs AN-REC (median(AN-REC) = 11.1 pg/ml, IQR(AN-REC) = 8.6-15.5, and p < 0.0001), and AN-REC vs CTRLS (p = 0.004). The plasma levels of NfL are negatively associated with BMI overall samples (beta (+/- se) = -0.62 +/- 0.087 and p = 6.9. 10(-12)). This indicates that AN is associated with neuronal damage that partially normalizes with weight recovery. Further studies are needed to determine which brain areas are affected, and potential long-term sequelae.
  • Yang, Xinping, et al. (författare)
  • Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing
  • 2016
  • Ingår i: Cell. - 0092-8674 .- 1097-4172. ; 164:4, s. 805-817
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>While alternative splicing is known to diversify the functional characteristics of some genes, the extent to which protein isoforms globally contribute to functional complexity on a proteomic scale remains unknown. To address this systematically, we cloned full-length open reading frames of alternatively spliced transcripts for a large number of human genes and used protein-protein interaction profiling to functionally compare hundreds of protein isoform pairs. The majority of isoform pairs share less than 50% of their interactions. In the global context of interactome network maps, alternative isoforms tend to behave like distinct proteins rather than minor variants of each other. Interaction partners specific to alternative isoforms tend to be expressed in a highly tissue-specific manner and belong to distinct functional modules. Our strategy, applicable to other functional characteristics, reveals a widespread expansion of protein interaction capabilities through alternative splicing and suggests that many alternative "isoforms'' are functionally divergent (i.e., "functional alloforms'').</p>
  • Shigeto, Makoto, et al. (författare)
  • GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
  • 2015
  • Ingår i: Journal of Clinical Investigation. - 0021-9738. ; 125:12, s. 4714-4728
  • Tidskriftsartikel (refereegranskat)abstract
    • Strategies aimed at mimicking or enhancing the action of the incretin hormone glucagon-like peptide 1 (GLP-1) therapeutically improve glucose-stimulated insulin secretion (GSIS); however, it is not clear whether GLP-1 directly drives insulin secretion in pancreatic islets. Here, we examined the mechanisms by which GLP-1 stimulates insulin secretion in mouse and human islets. We found that GLP-1 enhances GSIS at a half-maximal effective concentration of 0.4 pM. Moreover, we determined that GLP-1 activates PLC, which increases submembrane diacylglycerol and thereby activates PKC, resulting in membrane depolarization and increased action potential firing and subsequent stimulation of insulin secretion. The depolarizing effect of GLP-1 on electrical activity was mimicked by the PKC activator PMA, occurred without activation of PKA, and persisted in the presence of PKA inhibitors, the K-ATP channel blacker tolbutamide, and the L-type Ca2+ channel blacker isradipine; however, depolarization was abolished by lowering extracellular Na+. The PKC-dependent effect of GLP-1 on membrane potential and electrical activity was mediated by activation of NW-permeable TRPM4 and TRPM5 channels by mobilization of intracellular Ca2+ from thapsigargin-sensitive Ca2+ stores. Concordantly, GLP-1 effects were negligible in Trpm4 or Trpm5 KO islets. These data provide important insight into the therapeutic action of GLP-1 and suggest that circulating levels of this hormone directly stimulate insulin secretion by beta cells.
  • Soriano, Sergi, et al. (författare)
  • Rapid Insulinotropic Action of Low Doses of Bisphenol-A on Mouse and Human Islets of Langerhans: Role of Estrogen Receptor beta
  • 2012
  • Ingår i: PLoS ONE. - Public Library of Science. - 1932-6203. ; 7:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Bisphenol-A (BPA) is a widespread endocrine-disrupting chemical (EDC) used as the base compound in the manufacture of polycarbonate plastics. It alters pancreatic beta-cell function and can be considered a risk factor for type 2 diabetes in rodents. Here we used ER beta(-/-) mice to study whether ER beta is involved in the rapid regulation of K-ATP channel activity, calcium signals and insulin release elicited by environmentally relevant doses of BPA (1 nM). We also investigated these effects of BPA in beta-cells and whole islets of Langerhans from humans. 1 nM BPA rapidly decreased K-ATP channel activity, increased glucose-induced [Ca2+](i) signals and insulin release in beta-cells from WT mice but not in cells from ER beta(-/-) mice. The rapid reduction in the K-ATP channel activity and the insulinotropic effect was seen in human cells and islets. BPA actions were stronger in human islets compared to mouse islets when the same BPA concentration was used. Our findings suggest that BPA behaves as a strong estrogen via nuclear ER beta and indicate that results obtained with BPA in mouse beta-cells may be extrapolated to humans. This supports that BPA should be considered as a risk factor for metabolic disorders in humans.
  • Taneera, J., et al. (författare)
  • Orphan G-protein coupled receptor 183 (GPR183) potentiates insulin secretion and prevents glucotoxicity-induced β-cell dysfunction
  • 2020
  • Ingår i: Molecular and Cellular Endocrinology. - 0303-7207. ; 499
  • Tidskriftsartikel (refereegranskat)abstract
    • The expression and functional impact of most expression orphan G-protein coupled receptors (GPCRs) in β-cell is not fully understood. Microarray expression indicated that 36 orphan GPCRs are restricted in human islets, while 55 receptors overlapped between human islets and INS-1 cells. GPR183 showed higher expression in diabetic compared to non-diabetic human islets. GPR183 expression co-localized with β-cells while it was lacking in α-cells in human islets. The GPR183 agonist (7α-25-DHC) potentiated insulin secretion and protected against glucotoxicity-induced β-cell damage in human islets. Silencing of GPR183 in INS-1 cells decreased the expression of proinsulin genes, Pdx1, Mafa and impaired insulin secretion with a concomitant decrease in cAMP generation. Cultured INS-1 cells with 7α-25-DHC were associated with increased proliferation and expression of GPR183, INS2, PDX1, NeuroD, and INSR. In conclusion, the beneficial impact of GPR183 activation on β-cell function makes it a potential therapeutic target to prevent or reverse β-cell dysfunction. © 2019
  • Vergari, E., et al. (författare)
  • Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
  • 2019
  • Ingår i: Nature Communications. - 2041-1723. ; 10
  • Tidskriftsartikel (refereegranskat)abstract
    • Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of insulin-treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion, which restores normal plasma glucose levels by stimulation of hepatic glucose production. This counterregulatory mechanism is impaired in diabetes. Here we show in mice that therapeutic concentrations of insulin inhibit glucagon secretion by an indirect (paracrine) mechanism mediated by stimulation of intra-islet somatostatin release. Insulin's capacity to inhibit glucagon secretion is lost following genetic ablation of insulin receptors in the somatostatin-secreting δ-cells, when insulin-induced somatostatin secretion is suppressed by dapagliflozin (an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists. Administration of these compounds in vivo antagonises insulin's hypoglycaemic effect. We extend these data to isolated human islets. We propose that SSTR or SGLT2 antagonists should be considered as adjuncts to insulin in diabetes therapy.
  • Zhang, Quan, et al. (författare)
  • R-type Ca2+-channel-evoked CICR regulates glucose-induced somatostatin secretion
  • 2007
  • Ingår i: Nature Cell Biology. - Nature Publishing Group. - 1465-7392. ; 9:4, s. 171-453
  • Tidskriftsartikel (refereegranskat)abstract
    • Pancreatic islets have a central role in blood glucose homeostasis. In addition to insulin-producing beta-cells and glucagon-secreting alpha-cells, the islets contain somatostatin-releasing delta-cells(1). Somatostatin is a powerful inhibitor of insulin and glucagon secretion(2). It is normally secreted in response to glucose(3) and there is evidence suggesting its release becomes perturbed in diabetes(4). Little is known about the control of somatostatin release. Closure of ATP-regulated K+-channels (K-ATP-channels)(5) and a depolarization-evoked increase in cytoplasmic free Ca2+ concentration ([Ca2+](i))(6-8) have been proposed to be essential. Here, we report that somatostatin release evoked by high glucose (>= 10 mM) is unaffected by the K-ATP-channel activator diazoxide and proceeds normally in K-ATP-channel-deficient islets. Glucose-induced somatostatin secretion is instead primarily dependent on Ca2+-induced Ca2+-release (CICR). This constitutes a novel mechanism for K-ATP-channel-independent metabolic control of pancreatic hormone secretion.
  • Alonso-Magdalena, Paloma, et al. (författare)
  • Antidiabetic Actions of an Estrogen Receptor beta Selective Agonist
  • 2013
  • Ingår i: Diabetes. - American Diabetes Association Inc.. - 1939-327X. ; 62:6, s. 2015-2025
  • Tidskriftsartikel (refereegranskat)abstract
    • The estrogen receptor beta (ER beta) is emerging as an important player in the physiology of the endocrine pancreas. We evaluated the role and antidiabetic actions of the ER beta selective agonist WAY200070 as an insulinotropic molecule. We demonstrate that WAY200070 enhances glucose-stimulated insulin secretion both in mouse and human islets. In vivo experiments showed that a single administration of WAY200070 leads to an increase in plasma insulin levels with a concomitant improved response to a glucose load. Two-week treatment administration increased glucose-induced insulin release and pancreatic beta-cell mass and improved glucose and insulin sensitivity. In addition, streptozotocin-nicotinamide-induced diabetic mice treated with WAY200070 exhibited a significant improvement in plasma insulin levels and glucose tolerance as well as a regeneration of pancreatic beta-cell mass. Studies performed in db/db mice demonstrated that this compound restored first-phase insulin secretion and enhanced pancreatic beta-cell mass. We conclude that ER beta agonists should be considered as new targets for the treatment of diabetes.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 27
  • [1]23Nästa
fritt online (5)
Typ av publikation
tidskriftsartikel (23)
konferensbidrag (3)
annan publikation (1)
Typ av innehåll
refereegranskat (24)
övrigt vetenskapligt (4)
Salehi, A. (9)
Salehi, S Albert, (5)
Westerblad, H, (3)
Katz, A. (3)
Zhang, Q. (3)
Berggren, PO, (2)
visa fler...
Renström, Erik, (2)
Hamilton, A., (2)
Ashcroft, Frances M. ... (2)
Braun, M. (1)
Gupta, A. (1)
Blomgren, Henrik, 19 ... (1)
Lundquist, Ingmar, (1)
Adam, J. (1)
Malek, A. (1)
Roy, P. (1)
Bengtsson, M (1)
Zetterberg, H (1)
Dayeh, Tasnim, (1)
Froguel, Philippe, (1)
Lyssenko, Valeriya, (1)
Tuomi, Tiinamaija, (1)
Groop, Leif, (1)
Blennow, Kaj, 1958-, (1)
Blennow, K (1)
Landén, Mikael, 1966 ... (1)
Landen, M, (1)
Renstrom, E., (1)
Ahlqvist, Emma, (1)
Poon, Wenny, (1)
Fadista, Joao, (1)
Hansson, Ola, (1)
Wierup, Nils, (1)
Johansson, S, (1)
Oras, Jonatan, 1978- ... (1)
Block, Linda, (1)
Zetterberg, Henrik, ... (1)
Wagner, A., (1)
Nilsson, M (1)
Zhang, Quan, (1)
Rorsman, Patrik, (1)
Strigard, K (1)
Nordenskjold, A, (1)
Nilsson, Peter, (1)
Fredholm, BB, (1)
Johansson, SM (1)
Syvänen, Ann-Christi ... (1)
Vidal, Marc (1)
Ling, Charlotte, (1)
Wareham, Nicholas J (1)
visa färre...
Lunds universitet (11)
Karolinska Institutet (11)
Göteborgs universitet (7)
Kungliga Tekniska Högskolan (3)
Uppsala universitet (2)
Luleå tekniska universitet (1)
visa fler...
Chalmers tekniska högskola (1)
visa färre...
Engelska (27)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (18)
Samhällsvetenskap (4)
Naturvetenskap (1)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy